GlycoMimetics Inc (GLYC) Expected to Earn Q1 2019 Earnings of ($0.33) Per Share

GlycoMimetics Inc (NASDAQ:GLYC) – Equities researchers at SunTrust Banks issued their Q1 2019 EPS estimates for GlycoMimetics in a report released on Wednesday, March 6th. SunTrust Banks analyst P. Lawson anticipates that the biotechnology company will post earnings of ($0.33) per share for the quarter. SunTrust Banks also issued estimates for GlycoMimetics’ Q2 2019 earnings at ($0.35) EPS, Q3 2019 earnings at ($0.35) EPS, Q4 2019 earnings at ($0.37) EPS and FY2023 earnings at ($0.61) EPS.

GLYC has been the subject of several other research reports. ValuEngine cut GlycoMimetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 27th. Zacks Investment Research cut GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Thursday. BidaskClub upgraded GlycoMimetics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. Finally, HC Wainwright began coverage on GlycoMimetics in a research note on Tuesday, December 18th. They issued a “buy” rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $23.75.

Shares of GLYC opened at $11.01 on Friday. GlycoMimetics has a 1 year low of $8.29 and a 1 year high of $19.80.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC raised its position in shares of GlycoMimetics by 1.1% during the 3rd quarter. FMR LLC now owns 3,801,483 shares of the biotechnology company’s stock worth $54,741,000 after acquiring an additional 40,887 shares in the last quarter. BlackRock Inc. raised its position in shares of GlycoMimetics by 1.8% during the 3rd quarter. BlackRock Inc. now owns 2,853,504 shares of the biotechnology company’s stock worth $41,090,000 after acquiring an additional 50,353 shares in the last quarter. Redmile Group LLC raised its position in shares of GlycoMimetics by 0.9% during the 3rd quarter. Redmile Group LLC now owns 2,048,147 shares of the biotechnology company’s stock worth $29,493,000 after acquiring an additional 18,800 shares in the last quarter. Vanguard Group Inc. raised its position in shares of GlycoMimetics by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,691,550 shares of the biotechnology company’s stock worth $24,358,000 after acquiring an additional 26,951 shares in the last quarter. Finally, Vanguard Group Inc raised its position in shares of GlycoMimetics by 1.6% during the 3rd quarter. Vanguard Group Inc now owns 1,691,550 shares of the biotechnology company’s stock worth $24,358,000 after acquiring an additional 26,951 shares in the last quarter.

About GlycoMimetics

GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.

See Also: Understanding each part of a balance sheet

Earnings History and Estimates for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply